Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% (Sildenafil Cream) in women with female sexual arousal disorder (FSAD) will be presented at the upcoming International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting. These data include efficacy results across multiple endpoints in the proposed Phase 3 study population.
- “The results highlight specific endpoints with the strongest responses including arousal sensation, desire, orgasm, as well as stress, guilt, and embarrassment about the sexual dysfunction.
- Notably, Sildenafil Cream enhanced solo, unpartnered sexual experiences, which represented approximately 1 in 5 sexual events in the Phase 2b RESPOND study.
- “We are excited to share additional data from this groundbreaking study in one of the leading forums for scientific research on female sexual dysfunction,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
- Daré Bioscience previously announced a positive end-of-Phase 2 meeting with the FDA supporting advancement of Sildenafil Cream for the treatment of FSAD.